Literature DB >> 35107418

Serial Intervals and Household Transmission of SARS-CoV-2 Omicron Variant, South Korea, 2021.

Jin Su Song, Jihee Lee, Miyoung Kim, Hyeong Seop Jeong, Moon Su Kim, Seong Gon Kim, Han Na Yoo, Ji Joo Lee, Hye Young Lee, Sang-Eun Lee, Eun Jin Kim, Jee Eun Rhee, Il Hwan Kim, Young-Joon Park.   

Abstract

To clarify transmissibility of the severe acute respiratory syndrome coronavirus 2 Omicron variant, we determined serial intervals and secondary attack rates among household contacts in South Korea. Mean serial interval for 12 transmission pairs was 2.9 days, and secondary attack rate among 25 households was 50.0%, raising concern about a rapid surge in cases.

Entities:  

Keywords:  2019 novel coronavirus disease; COVID-19; Omicron; SARS-CoV-2; South Korea; coronavirus disease; respiratory infections; severe acute respiratory syndrome coronavirus 2; variant of concern; viruses; zoonoses

Mesh:

Year:  2022        PMID: 35107418      PMCID: PMC8888239          DOI: 10.3201/eid2803.212607

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron (B.1.1.529) variant of concern has been confirmed on all continents and has spread through communities around the world at unprecedented speed (). Given uncertainties about current estimates of virus transmissibility, we analyzed real-life data on serial intervals for transmission pairs (time from infector symptom onset to infectee symptom onset) and secondary attack rate among household contacts, offering metrics essential for predicting epidemic size, forecasting healthcare demand, and devising effective public health interventions. Details of the epidemiologic situation with regard to importation and transmission of the Omicron variant in South Korea have been described elsewhere (). We further traced a total of 76 case-patients with Omicron infection that originated from 2 persons with imported cases (75 confirmed cases and 1 suspected case) and their contacts, focusing on infector-infectee relationships and household transmission during November–December 2021. Because of the possibility of their being exposed to other potential sources of infection at church on November 28, 2021, we excluded infectees who had visited church on that date from transmission pairs. As for the time of infection in households, we assumed that the earliest exposure occurred 2 days before symptom onset of an infector and the last exposure before isolation of the infector. To calculate serial intervals, we did not include case-patients without a clear date of symptom onset. We defined a household as a group of persons living in the same residence with a shared space. This study was conducted as a legally mandated public health investigation under the authority of the Korean Infectious Diseases Control and Prevention Act (no. 12444 and no. 13392). The study was not research that was subject to institutional review board approval; therefore, written informed consent was not required. We identified 25 households, comprising 55 household members. Only 1 household comprised South Korea nationals; the others, foreign nationals. Of the 55 household members, 36 were confirmed to be Omicron-positive, among which secondary attack rate was 0.65 (95% CI 0.48–0.81). After we excluded the 18 household members who had visited church on November 28, 2021, the remaining 18 were confirmed to be Omicron case-patients; secondary attack rate among the 18 was 0.50 (95% CI 0.35–0.72) (Table).
Table

Characteristics of SARS-CoV-2 Omicron (B.1.1.529) variant of concern of index case-patients and household members, South Korea, 2021*

Household Index case-patient
Household members†
Age, y/sexTransmission routeSigns/symptoms at diagnosisCOVID-19 vaccination status (vaccine)‡No. members, n = 36No. confirmed cases, n = 18
1
44/M
Imported case
Cough, sputum, sore throat
Fully (mRNA-1273)

2
1
2
38/M
Contact with a confirmed case at the airport
Fever, cough, myalgia
Unvaccinated

2
1
3
33/M
Contact at church and restaurant
Fever, cough, myalgia, headache
Unvaccinated

1
1
4
39/F
Contact at church
Fever, myalgia
Partially (BNT162b)

1
0
5
31/F
Contact at church
Myalgia
Unvaccinated

0
0
6
27/F
Contact at church
Fever, sore throat
Unvaccinated

1
1
7
33/F
Contact at church
Fever, chill, cough, myalgia, headache
Unvaccinated

2
2
8
34/F
Contact at church
Sore throat
Unvaccinated

2
1
9
50/F
Contact at church
Cough, sore throat, headache
Fully (Ad26.COV2.S)

1
1
10
56/F
Contact with a friend
Cough, fatigue
Fully (Ad26.COV2.S)

0
0
11
46/M
Contact at church
Asymptomatic
Fully (mRNA-1273)

0
0
12
39/F
Contact at a restaurant
Sore throat
Unvaccinated

2
2
13
77/F
Contact at church
Cough, sore throat
Fully (BNT162b)

2
0
14
44/F
Contact at church
Sputum, sore throat
Fully (mRNA-1273)

1
1
15
6/M
Contact at a childcare center
Asymptomatic
Unvaccinated

2
0
16
31/F
Contact at church
Fever, sputum, sore throat
Unvaccinated

1
0
17
23/F
Contact with a friend
Fever, chill, cough, sputum, sore throat, myalgia, headache
Fully (mRNA-1273)

1
0
18
4/M
Contact at street
Asymptomatic
Unvaccinated

3
0
19
64/F
Contact at church
Asymptomatic
Fully (mRNA-1273)

0
0
20
67/F
Contact at church
Asymptomatic
Unvaccinated

1
1
21
34/F
Contact at church
Fever, myalgia
Unvaccinated

1
1
22
33/F
Contact at church
Sore throat, rhinorrhea
Fully (BNT162b)

2
0
23
45/F
Contact with a family member
Asymptomatic
Fully (Ad26.COV2.S)

2
1
24
2/F
Contact at playground
Fever, rhinorrhea
Unvaccinated

4
3
25
3/M
Contact at a childcare center
Asymptomatic
Unvaccinated

2
1
Total

NA
NA
NA

36
18
Attack rateNANANANA0.50

*COVID-19, coronavirus disease; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2. †Household members who participated in church service on November 28, 2021, were excluded. ‡An unvaccinated person had received no COVID-19 vaccine. A partially vaccinated person had received a COVID-19 vaccine but had not completed the primary series >14 d before illness onset. A fully vaccinated person had completed the primary series of COVID-19 vaccine >14 d before illness onset; vaccinated index case-patients received BNT162b, n = 3; mRNA-1273, n = 5; or Ad26.COV2.S, n = 3.

*COVID-19, coronavirus disease; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2. †Household members who participated in church service on November 28, 2021, were excluded. ‡An unvaccinated person had received no COVID-19 vaccine. A partially vaccinated person had received a COVID-19 vaccine but had not completed the primary series >14 d before illness onset. A fully vaccinated person had completed the primary series of COVID-19 vaccine >14 d before illness onset; vaccinated index case-patients received BNT162b, n = 3; mRNA-1273, n = 5; or Ad26.COV2.S, n = 3. We used 12 transmission pairs for the calculation, including 12 infectors and 19 infectees. Mean (± SD) ages were 34.2 (± 18.2) years for infectors and 32.5 (± 21.7) years for infectees. The mean incubation period of the transmission pairs was 2.5–4.3 days, and the median incubation period was 3–4 days. The mean (± SD) serial interval for the pairs was 2.9 (± 1.6) days; the median serial interval was 3.0 days (Appendix). The estimated mean serial interval of 2.9 days for Omicron was shorter than that determined for wild-type virus and the Delta variant found in other studies conducted in South Korea (,). Enhanced nonpharmaceutical interventions such as rapid isolation of case-patients, as revealed by the mean time of 0.75 (range 0–4) days from symptom onset to isolation among infectors, and meticulous contact tracing during the study period may have shortened the serial interval and reduced superspreading potential, as evidenced in other research (). Thus, further studies in other places or at other periods, are needed, using larger sample sizes to more accurately estimate transmission dynamics and effects of public health measures. The household secondary attack rate that we found, factoring in vaccination status and prior infections, was substantially higher than rates for wild type virus and the Delta variant of concern previously reported in South Korea and other countries (). This finding is in line with earlier reports that suggested increased household risk for transmission of Omicron variant (,), although enhanced isolation in conjunction with a comprehensive testing strategy for contacts of case-patients may partially inflate secondary attack rate in our study. Of note, in our study, the secondary attack rate among fully vaccinated persons is high (62.5%, 10/16), thus heightening concerns over immune escape and the possibility that Omicron may be associated with considerably reduced vaccine effectiveness. However, further studies are needed to accurately assess the relative roles of increased intrinsic transmissibility and immune escape. Our findings with regard to Omicron transmissibility by symptomatic index case-patients supports that of a meta-analysis reporting that that secondary attack rates were higher in households with symptomatic rather than asymptomatic index case-patients (). However, caution is warranted when interpreting our results because other social and demographic factors could not be properly adjusted and sample size was too small to ensure adequate statistical power. Our findings of a short serial interval among transmission pairs and a high secondary attack rate among household members adds timely real-life evidence of increased transmissibility of the Omicron variant of concern along with the potential for immune escape, thus necessitating a package of effective public health measures to mitigate the spread of Omicron in each country.

Appendix

Supplemental information for transmission pairs infected with severe acute respiratory syndrome coronavirus 2 Omicron (B.1.1.529) variant of concern, South Korea, 2021.
  5 in total

1.  The Serial Interval of COVID-19 in Korea: 1,567 Pairs of Symptomatic Cases from Contact Tracing.

Authors:  Kwan Hong; Sujin Yum; Jeehyun Kim; Byung Chul Chun
Journal:  J Korean Med Sci       Date:  2020-12-28       Impact factor: 2.153

2.  Household Transmission of SARS-CoV-2: A Systematic Review and Meta-analysis.

Authors:  Zachary J Madewell; Yang Yang; Ira M Longini; M Elizabeth Halloran; Natalie E Dean
Journal:  JAMA Netw Open       Date:  2020-12-01

3.  Serial Interval and Transmission Dynamics during SARS-CoV-2 Delta Variant Predominance, South Korea.

Authors:  Sukhyun Ryu; Dasom Kim; Jun-Sik Lim; Sheikh Taslim Ali; Benjamin J Cowling
Journal:  Emerg Infect Dis       Date:  2021-12-14       Impact factor: 6.883

4.  Importation and Transmission of SARS-CoV-2 B.1.1.529 (Omicron) Variant of Concern in Korea, November 2021.

Authors:  Ji Joo Lee; Young June Choe; Hyeongseop Jeong; Moonsu Kim; Seonggon Kim; Hanna Yoo; Kunhee Park; Chanhee Kim; Sojin Choi; JiWoo Sim; Yoojin Park; In Sil Huh; Gasil Hong; Mi Young Kim; Jin Su Song; Jihee Lee; Eun-Jin Kim; Jee Eun Rhee; Il-Hwan Kim; Jin Gwack; Jungyeon Kim; Jin-Hwan Jeon; Wook-Gyo Lee; Suyeon Jeong; Jusim Kim; Byungsik Bae; Ja Eun Kim; Hyeonsoo Kim; Hye Young Lee; Sang-Eun Lee; Jong Mu Kim; Hanul Park; Mi Yu; Jihyun Choi; Jia Kim; Hyeryeon Lee; Eun-Jung Jang; Dosang Lim; Sangwon Lee; Young-Joon Park
Journal:  J Korean Med Sci       Date:  2021-12-27       Impact factor: 2.153

5.  Serial interval of SARS-CoV-2 was shortened over time by nonpharmaceutical interventions.

Authors:  Sheikh Taslim Ali; Lin Wang; Eric H Y Lau; Xiao-Ke Xu; Zhanwei Du; Ye Wu; Gabriel M Leung; Benjamin J Cowling
Journal:  Science       Date:  2020-07-21       Impact factor: 47.728

  5 in total
  16 in total

1.  Increased Secondary Attack Rates among the Household Contacts of Patients with the Omicron Variant of the Coronavirus Disease 2019 in Japan.

Authors:  Tsuyoshi Ogata; Hideo Tanaka; Emiko Tanaka; Natsumi Osaki; Etsuko Noguchi; Yukino Osaki; Ayane Tono; Koji Wada
Journal:  Int J Environ Res Public Health       Date:  2022-06-30       Impact factor: 4.614

2.  Transmission Potential of the Omicron Variant of Severe Acute Respiratory Syndrome Coronavirus 2 in South Korea, 25 November 2021-8 January 2022.

Authors:  Eunha Shim; Wongyeong Choi; Donghyok Kwon; Taeyoung Kim; Youngji Song
Journal:  Open Forum Infect Dis       Date:  2022-05-13       Impact factor: 4.423

3.  Older Adults Mount Less Durable Humoral Responses to Two Doses of COVID-19 mRNA Vaccine but Strong Initial Responses to a Third Dose.

Authors:  Francis Mwimanzi; Hope R Lapointe; Peter K Cheung; Yurou Sang; Fatima Yaseen; Gisele Umviligihozo; Rebecca Kalikawe; Sneha Datwani; F Harrison Omondi; Laura Burns; Landon Young; Victor Leung; Olga Agafitei; Siobhan Ennis; Winnie Dong; Simran Basra; Li Yi Lim; Kurtis Ng; Ralph Pantophlet; Chanson J Brumme; Julio S G Montaner; Natalie Prystajecky; Christopher F Lowe; Mari L DeMarco; Daniel T Holmes; Janet Simons; Masahiro Niikura; Marc G Romney; Zabrina L Brumme; Mark A Brockman
Journal:  J Infect Dis       Date:  2022-09-21       Impact factor: 7.759

4.  Older Adults Mount Less Durable Humoral Responses to a Two-dose COVID-19 mRNA Vaccine Regimen, but Strong Initial Responses to a Third Dose.

Authors:  Francis Mwimanzi; Hope R Lapointe; Peter K Cheung; Yurou Sang; Fatima Yaseen; Gisele Umviligihozo; Rebecca Kalikawe; Sneha Datwani; F Harrison Omondi; Laura Burns; Landon Young; Victor Leung; Olga Agafitei; Siobhan Ennis; Winnie Dong; Simran Basra; Li Yi Lim; Kurtis Ng; Ralph Pantophlet; Chanson J Brumme; Julio S G Montaner; Natalie Prystajecky; Christopher F Lowe; Mari L DeMarco; Daniel T Holmes; Janet Simons; Masahiro Niikura; Marc G Romney; Zabrina L Brumme; Mark A Brockman
Journal:  medRxiv       Date:  2022-02-21

5.  SARS-CoV-2 B.1.1.529 (Omicron) Variant Transmission Within Households - Four U.S. Jurisdictions, November 2021-February 2022.

Authors:  Julia M Baker; Jasmine Y Nakayama; Michelle O'Hegarty; Andrea McGowan; Richard A Teran; Stephen M Bart; Katie Mosack; Nicole Roberts; Brooke Campos; Alina Paegle; John McGee; Robert Herrera; Kayla English; Carla Barrios; Alexandria Davis; Christine Roloff; Lynn E Sosa; Jessica Brockmeyer; Lindsey Page; Amy Bauer; Joshua J Weiner; Manjeet Khubbar; Sanjib Bhattacharyya; Hannah L Kirking; Jacqueline E Tate
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2022-03-04       Impact factor: 17.586

6.  Duration of viable virus shedding in SARS-CoV-2 omicron variant infection.

Authors:  Julie Boucau; Caitlin Marino; James Regan; Rockib Uddin; Manish C Choudhary; James P Flynn; Geoffrey Chen; Ashley M Stuckwisch; Josh Mathews; May Y Liew; Arshdeep Singh; Taryn Lipiner; Autumn Kittilson; Meghan Melberg; Yijia Li; Rebecca F Gilbert; Zahra Reynolds; Surabhi L Iyer; Grace C Chamberlin; Tammy D Vyas; Marcia B Goldberg; Jatin M Vyas; Jonathan Z Li; Jacob E Lemieux; Mark J Siedner; Amy K Barczak
Journal:  medRxiv       Date:  2022-03-02

7.  Rapid increase in SARS-CoV-2 seroprevalence during the emergence of Omicron variant, Finland.

Authors:  Maarit J Ahava; Hanna Jarva; Anne J Jääskeläinen; Maija Lappalainen; Olli Vapalahti; Satu Kurkela
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2022-04-28       Impact factor: 5.103

8.  Household Secondary Attack Rates of SARS-CoV-2 by Variant and Vaccination Status: An Updated Systematic Review and Meta-analysis.

Authors:  Zachary J Madewell; Yang Yang; Ira M Longini; M Elizabeth Halloran; Natalie E Dean
Journal:  JAMA Netw Open       Date:  2022-04-01

9.  Policy choices for Shanghai responding to challenges of Omicron.

Authors:  Ying Qian; Siqi Cao; Laijun Zhao; Yuge Yan; Jiaoling Huang
Journal:  Front Public Health       Date:  2022-08-09

10.  Neutralizing Activity Against SARS-CoV-2 Delta and Omicron Variants Following a Third BNT162b2 Booster Dose According to Three Homologous or Heterologous COVID-19 Vaccination Schedules.

Authors:  Ju-Yeon Choi; Young Jae Lee; Jae-Hoon Ko; Su-Hwan Kim; Hye-Jin Kim; Hye Won Lee; Hyeonji Jeong; Tae-Yong Kim; Yeong Gyeong Jang; Hyo-Jeong Hong; Min-Seong Kim; Sang Eun Lee; Yong Guan Kim; Eun Joo Chung; Heeji Lim; Sundong Jang; Kwangwook Kim; Sung Soon Kim; Jin Young Ahn; Jun Yong Choi; Yong Chan Kim; Yoon Soo Park; Kyong Ran Peck; Byoungguk Kim
Journal:  Front Cell Infect Microbiol       Date:  2022-07-11       Impact factor: 6.073

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.